Retrospective study on the benefits of combined memantine and cholin esterase inhibitor treatment in AGEd patients affected with Alzheimer's Disease: The MEMAGE Study

Journal of Alzheimer's Disease

Volumn 41, Issue 2, 2014, Pages 633-640

  Gareri, Pietro ^a   Putignano, Daria ^b   Castagna, Alberto ^c   Cotroneo, Antonino Maria ^d   De Palo, Grazia ^e   Fabbo, Andrea ^c   Forgione, Luigi ^f   Giacummo, Attilio ^g   Lacava, Roberto ^a   Marino, Saverio ^h   Simone, Maurizio ^h   Zurlo, Amedeo ⁱ   Putignano, Salvatore ^g  

^a ASP Catanzaro   (Italy)

^b Metabolic and Aging Science   (Italy)

^c AUSL Modena   (Italy)

^d ASL2 Turin   (Italy)

^e DS 3 ASL Bitonto   (Italy)

^f ASL Napoli 3 Sud   (Italy)

^g ASL NA 1   (Italy)

^h Elderly Assistance Unit   (Italy)

ⁱ UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Acetylcholinesterase inhibitor drugs; Alzheimer's disease; Elderly; Memantine

Indexed keywords

CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; INDAN DERIVATIVE; MEMANTINE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; COMORBIDITY; DAILY LIFE ACTIVITY; DRUG EFFECTS; FEMALE; HUMAN; ITALY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; COMORBIDITY; FEMALE; GALANTAMINE; HUMANS; INDANS; ITALY; MALE; MEMANTINE; MIDDLE AGED; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927566004     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132735     Document Type: Article

References (32)

1. Mayeux R, Stern Y (2012) Epidemiology of Alzheimer disease. Cold Spring Harb Perspect 2, 8.
2. Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology 76, 27-50.
3. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1, CD005593.
4. McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev, CD003154.
5. Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ (2007) Memantine in moderate to severe Alzheimer's disease: A meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24, 20-27.
6. Parsons CG, Danysz W, Dekundy A, Pulte I (2013) Memantine and cholinesterase inhibitors: Complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res 24, 358-369.
7. Nyakas C, Granic I, Halmy LG, Banerjee P, Luiten PG (2011) The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-b42 with memantine. Behav Brain Res 221, 594-603.
8. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study, Group (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291, 317-324.
9. Cummings JL, Schneider E, Tariot PN, Graham SM, Memantine MEM-MD-02 Study, Group (2006) Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67, 57-63.
10. Gauthier S, Molinuevo L (2012) Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimer Dement 9, 326-331.
11. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22, 209-221.
12. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80, 600-607.
13. Francis PT, Parsons CG, Jones RW (2012) Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. Expert Rev Neurother 12, 1351-1365.
14. Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT (2004) Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 38, 1389-1394.
15. Shua-Haim J, Smith J, Picard F, Sedek G, Athalye S, Pommier F, Lefevre G (2008) Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by coadministration of memantine: An open-label, crossover, single-centre study. Clin Drug Investig 28, 361-374.
16. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7, 263-269.
17. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
18. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 185, 914-919.
19. Lawton MP, Brody EM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 9, 179-186.
20. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
21. Linn BS, LinnMW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16, 622-626.
22. Muayqil T, Camicioli R (2012) Systematic review and metaanalysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias. Dement Geriatr Cogn Dis Extra 2, 546-572.
23. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG (2009) Management of agitation and aggression associated with Alzheimer's disease. Nat Rev Neurol 5, 245-255.
24. Corbett A, Smith J, Creese B, Ballard C (2012) Treatment of behavioral and psychological symptoms of Alzheimer's disease. Curr Treat Options Neurol 14, 113-125.
25. Ballard C, Corbett A (2013) Agitation and aggression in people with Alzheimer's disease. Curr Opin Psychiatry 26, 252-259.
26. Cumbo E, Ligori LD (2014) Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: A 12- month, randomized, open-label trial. J Alzheimers Dis 39, 477-485.
27. Herrmann N, Cappell J, Eryavec GM, Lanctôt KL (2011) Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: An open-label pilot study. CNS Drugs 25, 425-433.
28. Huang YJ, Lin CH, Lane HY, Tsai GE (2012) NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer's disease. Curr Neuropharmacol 10, 272-285.
29. Boyle LM (2013) A neuroplasticity hypothesis of chronic stress in basal amygdale. Yale J Biol 86, 117-125.
30. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. NEJM 366, 893-903.
31. Gauthier S, Molinuevo JL (2013) Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement 9, 326-331.
32. Clodomiro A, Gareri P, Puccio G, Frangipane F, Lacava R, Castagna A, Manfredi GL, Colao R, BruniAC(2013) Somatic comorbidities and Alzheimer's disease treatment. Neurol Sci 34, 1581-1589.